Status-neutral community-based multilevel intervention to address intersectional stigma and discrimination, and increase HIV testing, PrEP, and ART uptake among YGBMSM in Ghanaian Slums: A clustered randomized control trial protocol.
Antiretroviral Therapy
HIV
Healthcare
Intersectional Stigma
Pre-Exposure Prophylaxis
Testing
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
30 May 2024
30 May 2024
Historique:
pubmed:
10
6
2024
medline:
10
6
2024
entrez:
10
6
2024
Statut:
epublish
Résumé
While GBMSM constitute less than 2% of Ghana's population, their HIV prevalence surpasses the national average by more than eightfold, emphasizing the critical need for targeted interventions to improve detection, care linkage, and reduce community transmission. This study seeks to increase HIV testing, Pre-Exposure Prophylaxis (PrEP), and Antiretroviral Therapy (ART) uptake (HPART) among YGBMSM through the adaptation of an evidence-based intervention (LAFIYA). We will employ the ADAPTT-IT framework to adapt LAFIYA and evaluate its feasibility and effectiveness in addressing intersectional stigma and increasing HPART uptake among YGBMSM residing in Ghanaian slums. In aim 1, we will hold focus groups (n=5) and interviews (n=20) among YGBMSM and two FGDs among GBMSM-led organizations. At the HCF level, we will hold 6 FGDs and interviews (n=20) among nurses. In AIM 2, we will randomly assign 6 healthcare facilities (HCFs) to receive the LAFIYA (n=3) or wait-list control (n=3). Friend groups (cluster) of YGBMSM (N=240) will be assigned to receive LAFIYA (n=120) or a wait-list control (n=120). We will collect 3-, 6-, and 9-months post-intervention data among YGBMSM(n=240) and HCWs(n=300) to measure HPART adherence (primary outcomes), ISD reduction, HIV and status-neutral knowledge (secondary outcomes), and intervention acceptability, appropriateness, and feasibility (implementation outcomes). The intervention group will observe increased HPART adherence, reduced ISD, and enhanced HPART knowledge and efficacy relative to the wait-list control group. The findings will inform ISD reduction and HIV status-neutral implementation strategies - and place-based interventions that address access to HIV prevention and care among YGBMSM, slum and in different settings. This study was registered on clinicalTrail.gov, with identifier number NCT06312514 on 03/14/2023. https://classic.clinicaltrials.gov/ct2/show/NCT06312514.
Sections du résumé
Background
UNASSIGNED
While GBMSM constitute less than 2% of Ghana's population, their HIV prevalence surpasses the national average by more than eightfold, emphasizing the critical need for targeted interventions to improve detection, care linkage, and reduce community transmission. This study seeks to increase HIV testing, Pre-Exposure Prophylaxis (PrEP), and Antiretroviral Therapy (ART) uptake (HPART) among YGBMSM through the adaptation of an evidence-based intervention (LAFIYA).
Methodology
UNASSIGNED
We will employ the ADAPTT-IT framework to adapt LAFIYA and evaluate its feasibility and effectiveness in addressing intersectional stigma and increasing HPART uptake among YGBMSM residing in Ghanaian slums. In aim 1, we will hold focus groups (n=5) and interviews (n=20) among YGBMSM and two FGDs among GBMSM-led organizations. At the HCF level, we will hold 6 FGDs and interviews (n=20) among nurses. In AIM 2, we will randomly assign 6 healthcare facilities (HCFs) to receive the LAFIYA (n=3) or wait-list control (n=3). Friend groups (cluster) of YGBMSM (N=240) will be assigned to receive LAFIYA (n=120) or a wait-list control (n=120). We will collect 3-, 6-, and 9-months post-intervention data among YGBMSM(n=240) and HCWs(n=300) to measure HPART adherence (primary outcomes), ISD reduction, HIV and status-neutral knowledge (secondary outcomes), and intervention acceptability, appropriateness, and feasibility (implementation outcomes).
Conclusion
UNASSIGNED
The intervention group will observe increased HPART adherence, reduced ISD, and enhanced HPART knowledge and efficacy relative to the wait-list control group. The findings will inform ISD reduction and HIV status-neutral implementation strategies - and place-based interventions that address access to HIV prevention and care among YGBMSM, slum and in different settings.
Trail Registration
UNASSIGNED
This study was registered on clinicalTrail.gov, with identifier number NCT06312514 on 03/14/2023. https://classic.clinicaltrials.gov/ct2/show/NCT06312514.
Identifiants
pubmed: 38854081
doi: 10.21203/rs.3.rs-4486078/v1
pmc: PMC11160908
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT06312514']
Types de publication
Journal Article
Preprint
Langues
eng
Déclaration de conflit d'intérêts
Additional Declarations: The authors declare no competing interests.
Références
AIDS Behav. 2017 Apr;21(4):1171-1182
pubmed: 27506817
BMC Health Serv Res. 2024 May 21;24(1):647
pubmed: 38773589
Front Public Health. 2021 Sep 21;9:694836
pubmed: 34621716
Prev Med Rep. 2021 Feb 23;22:101335
pubmed: 33680722
Glob Public Health. 2022 Jul;17(7):1200-1214
pubmed: 33977867
Front Public Health. 2021 Jun 11;9:660256
pubmed: 34178919
Trials. 2019 Jul 4;20(1):396
pubmed: 31272495
Arch Pediatr Adolesc Med. 1999 Sep;153(9):959-64
pubmed: 10482213
PLoS One. 2021 Nov 29;16(11):e0259324
pubmed: 34843529
Soc Sci Med. 2012 Apr;74(8):1261-8
pubmed: 22401646
J Behav Med. 2007 Oct;30(5):359-70
pubmed: 17588200
AIDS Patient Care STDS. 2022 Nov;36(11):443-450
pubmed: 36306520
AIDS Behav. 2021 Nov;25(11):3574-3604
pubmed: 33866444
BMC Public Health. 2017 Oct 3;17(1):770
pubmed: 28974257
J Racial Ethn Health Disparities. 2015 Mar;2(1):1-10
pubmed: 25960944
PLOS Glob Public Health. 2023 Dec 1;3(12):e0001659
pubmed: 38039264
J Homosex. 2007;53(4):201-21
pubmed: 18689198
Prev Sci. 2015 Nov;16(8):1147-58
pubmed: 26031542
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):447-56
pubmed: 24135734
BMC Public Health. 2017 Sep 6;17(1):693
pubmed: 28874157
AIDS Care. 2020 Aug;32(8):1036-1044
pubmed: 32362131
BMC Public Health. 2023 Jan 24;23(1):166
pubmed: 36694150
Glob Public Health. 2021 Jul;16(7):1028-1045
pubmed: 33050773
PLoS One. 2024 Jun 5;19(6):e0289905
pubmed: 38837972
AIDS Behav. 2022 May;26(5):1530-1543
pubmed: 34731405
J Urban Health. 2019 Feb;96(1):55-62
pubmed: 30328063
AIDS Care. 2020 Mar;32(3):330-336
pubmed: 31597455
AIDS Behav. 2023 May;27(Suppl 1):162-184
pubmed: 35907143
BMC Infect Dis. 2022 Aug 13;22(1):690
pubmed: 35964006
J Int Assoc Provid AIDS Care. 2023 Jan-Dec;22:23259582231209649
pubmed: 37933162
PLoS One. 2022 Oct 19;17(10):e0276209
pubmed: 36260550
Health Psychol. 1998 May;17(3):269-76
pubmed: 9619477
BMJ Open. 2021 Aug 6;11(8):e047280
pubmed: 34362801
Int J Environ Res Public Health. 2021 Dec 12;18(24):
pubmed: 34948712
Int J Behav Med. 2008;15(3):194-200
pubmed: 18696313
AIDS Res Treat. 2016;2016:5360180
pubmed: 27239340
Afr Health Sci. 2003 Apr;3(1):7-14
pubmed: 12789082
Health Place. 2023 Sep;83:103076
pubmed: 37423093
Health Place. 2012 Sep;18(5):1144-52
pubmed: 22591621
J Gen Intern Med. 2006 Dec;21(12):1288-94
pubmed: 16995893
BMC Med. 2019 Feb 15;17(1):31
pubmed: 30764826
PLOS Glob Public Health. 2023 Jun 7;3(6):e0001956
pubmed: 37285336
BMC Public Health. 2024 Apr 5;24(1):966
pubmed: 38580970
PLoS One. 2015 Jan 30;10(1):e0115504
pubmed: 25635774
Ghana Med J. 2019 Mar;53(1):59-62
pubmed: 31138945
J Int AIDS Soc. 2022 Jul;25 Suppl 1:e25908
pubmed: 35818873
AIDS Behav. 2018 Mar;22(3):829-839
pubmed: 28550380
AIDS Care. 2016;28(4):460-4
pubmed: 26643735
Int J Environ Res Public Health. 2022 Jan 17;19(2):
pubmed: 35055823
JMIR Public Health Surveill. 2016 Feb 05;2(1):e4
pubmed: 27227158
J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):185-93
pubmed: 22227488
Res Nurs Health. 2015 Jun;38(3):194-206
pubmed: 25809638
AIDS Behav. 2009 Jun;13(3):532-44
pubmed: 19267264
Am J Public Health. 2013 Dec;103(12):2193-9
pubmed: 24134345
Open AIDS J. 2018 Aug 31;12:69-80
pubmed: 30258509
PLOS Glob Public Health. 2024 Jan 11;4(1):e0002231
pubmed: 38206889
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:2325958220978113
pubmed: 33733909
J Acquir Immune Defic Syndr. 2008 Mar 1;47 Suppl 1:S40-6
pubmed: 18301133
J Int AIDS Soc. 2021 Sep;24(9):e25782
pubmed: 34473405